TABLE 1.
Characteristics of retrospective cohort according to vaccination status
| Unvaccinated (n = 194) | mRNA vaccination (n = 226) | p value | |
|---|---|---|---|
| Age (years) | 58 ± 13 | 58 ± 11 | .948 |
| Gender (male) | 130 (67) | 143 (63) | .485 |
| Time posttransplant (months) | 118 ± 85 | 88 ± 76 | <.001 |
| Previous transplantation | 21 (11) | 21 (9) | .720 |
| Cause of end stage renal disease | .054 | ||
| Chronic glomerulonephritis | 90 (46) | 111 (49) | |
| Diabetic nephropathy | 10 (5) | 14 (6) | |
| Polycystic kidney disease | 36 (19) | 40 (18) | |
| Hypertension/nephrosclerosis | 31 (16) | 21 (9) | |
| Other | 6 (16) | 34 (18) | |
| Duration of RRT (months) | 17 ± 17 | 19 ± 21 | .490 |
| Donor type (deceased) | 178 (92) | 210 (93) | .791 |
| Body mass index (kg/m2) | 29 ± 5 | 29 ± 5 | .087 |
| Diabetes | 44 (23) | 79 (35) | .008 |
| Hypertension | 192 (99) | 226 (100) | .413 |
| Cardiovascular disease | 55 (28) | 106 (47) | <.001 |
| Chronic pulmonary disease | 22 (11) | 26 (12) | .919 |
| Estimated GFRa (ml/min) | 49 ± 20 | 50 ± 20 | .993 |
| Immunosuppression at vaccination | |||
| Tacrolimus | 161 (83) | 195 (86) | .424 |
| Cyclosporine | 26 (13) | 25 (11) | .560 |
| Mycophenolate mofetil/sodium | 170 (88) | 200 (88) | .903 |
| Sirolimus | 5 (3) | 7 (3) | .980 |
| Depleting ALA within 6 months | 2 (1) | 2 (1) | .726 |
Note: Data are number of patients (percentage) or mean ± SD.
Abbreviations: ALA, antilymphocyte antibody; COVID-19, coronavirus disease 2019; GFR, glomerular filtration rate; RRT, renal replacement therapy.
a
According to CKD-EPI formula.